Source: Eur Respir J 2016; 47: 1235-1243
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tiberi Simon, Payen Marie-Christine, Sotgiu Giovanni, D'Ambrosio Lia, Alarcon Guizado Valentina, Alffenaar Jan Willem, Abdo Arbex Marcos, Caminero Jose A., Centis Rosella, De Lorenzo Saverio, Gaga Mina, Gualano Gina, Roby Arias Aurora Jazmín, Scardigli Anna, Skrahina Alena, Solovic Ivan, Sulis Giorgia, Tadolini Marina, Akkerman Onno W., Alarcon Arrascue Edith, Aleska Alena, Avchinko Vera, Bonini Eduardo Henrique, Chong Marín Félix Antonio, Collahuazo López Lorena, de Vries Gerard, Dore Simone, Kunst Heinke, Matteelli Alberto, Moschos Charalampos, Palmieri Fabrizio, Papavasileiou Apostolos, Spanevello Antonio, Vargas Vasquez Dante, Viggiani Pietro, White Veronica, Zumla Alimuddin, Migliori Giovanni Battista. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016; 47: 1235-1243

Member's Comments

No comment yet.

Related content which might interest you: Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47:1758-1766 Year: 2016 Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Treatment options for MDR- and XDR-TB Source: Eur Respir Monogr 2017; 75: 232-244 Year: 2017 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective Source: Eur Respir J 2010; 35: 936-938 Year: 2010 Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Efficiency of Bedaquiline in treatment of XDR-TB Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019 Year: 2019 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022